Health Canada Approves Lilly’s Mounjaro to Reduce Cardiovascular Risk
Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. The supplied body says it is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack and stroke risk.